TBVI in its business model considers the need to:
- innovate and diversify the TB vaccine and biomarker pipeline;
- early identify and support the most promising vaccine candidates through clinical development;
- ensure acceptability, access and affordability of new TB vaccines for the end user;
- accelerate TB vaccine R&D through partnership;
- deliver through TBVI, key service support to R&D partners including neutral and non-biased technical advice for clinical product development and portfolio priority selection decisions for funders;
- provide efficient and effective financial management and oversight;
- generate both social and economic returns for investors.
Elements of the business model:
- accelerating R&D through partnership:
- consortium approach for concept and idea generation; knowledge development, exchange; and collaborative research;
- partner with industry;
- support the development of and participate in global networks and partnerships;
- a portfolio management approach for entry of candidates into the pipeline and selection of candidates for support for preclinical and clinical development;
- promote innovation and ensure access;
- ownership and IP rest with research and vaccine development partners;
- upstream agreements with research partners and vaccine developers to promote access and affordability of the vaccine for the end user;
- provision of essential services to support R&D activities of partners;
- project identification, design and development;
- project management;
- resource mobilisation;
- knowledge development and exchange, and networking;
- technical support for product and clinical development.